| abstract |
The present disclosure provides a platform for the delivery of herpesvirus proteins, particularly complex-forming proteins in vivo, to cells. In some embodiments, these proteins and complexes they form induce potent neutralizing antibodies. Thus, the provision of a herpesvirus protein using the disclosed platform allows the generation of a broad and potent immune response useful for vaccine development. |